Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.

Several macrolides have been reported to cause QT prolongation and ventricular arrhythmias such as torsades de pointes. To clarify the underlying ionic mechanisms, we examined the effects of six macrolides on the human ether-a-go-go-related gene (HERG)-encoded potassium current stably expressed in human embryonic kidney-293 cells. All six drugs showed a concentration-dependent inhibition of the current with the following IC(50) values: clarithromycin, 32.9 microM; roxithromycin, 36.5 microM; erythromycin, 72.2 microM; josamycin, 102.4 microM; erythromycylamine, 273.9 microM; and oleandomycin, 339.6 microM. A metabolite of erythromycin, des-methyl erythromycin, was also found to inhibit HERG current with an IC(50) of 147.1 microM. These findings imply that the blockade of HERG may be a common feature of macrolides and may contribute to the QT prolongation observed clinically with some of these compounds. Mechanistic studies showed that inhibition of HERG current by clarithromycin did not require activation of the channel and was both voltage- and time-dependent. The blocking time course could be described by a first-order reaction between the drug and the channel. Both binding and unbinding processes appeared to speed up as the membrane was more depolarized, indicating that the drug-channel interaction may be affected by electrostatic responses.

[1]  W. Trautwein,et al.  “Run-down” of the Ca current during long whole-cell recordings in guinea pig heart cells: role of phosphorylation and intracellular calcium , 1988, Pflügers Archiv.

[2]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[3]  Elisabetta Poluzzi,et al.  Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus , 2001, European Journal of Clinical Pharmacology.

[4]  J. Westphal Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. , 2001, British journal of clinical pharmacology.

[5]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Rafflenbeul,et al.  QT prolongation due to roxithromycin , 2000, Postgraduate medical journal.

[7]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[9]  Y. Kurachi,et al.  Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  J. Camm,et al.  Risk of torsades de pointes with non-cardiac drugs , 2000, BMJ : British Medical Journal.

[11]  G. Amsden,et al.  Macrolide Drug Interactions: An Update , 2000, The Annals of pharmacotherapy.

[12]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[13]  M. Jiang,et al.  Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.

[14]  H. Yoshida,et al.  [Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats]. , 1999, The Japanese journal of antibiotics.

[15]  Cavero,et al.  QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.

[16]  K. Eguchi,et al.  Clarithromycin associated with torsades de pointes. , 1999, Japanese circulation journal.

[17]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[18]  B. Knollmann,et al.  Cardiac actions of erythromycin: influence of female sex. , 1998, JAMA.

[19]  A. Cohen,et al.  The influence of cisapride and clarithromycin on QT intervals in healthy volunteers , 1998, Clinical pharmacology and therapeutics.

[20]  S. Tang,et al.  QT prolongation and Torsades de Pointes associated with clarithromycin. , 1998, The American journal of medicine.

[21]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[22]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[23]  M. Sekkarie,et al.  Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  K. Hussain,et al.  A Review of Erythromycin-Induced Malignant Tachyarrhythmia— Torsade de Pointes , 1997, Angiology.

[25]  D. Rampe,et al.  Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  C. Lipinski,et al.  Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. , 1997, Journal of medicinal chemistry.

[27]  C. January,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, The American journal of physiology.

[28]  P. Saikku,et al.  Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. , 1996, Chest.

[29]  C Antzelevitch,et al.  Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.

[30]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[31]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.

[32]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[33]  O. G. Nilsen Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin , 1995, Infection.

[34]  D. Zipes,et al.  Electrophysiological Mechanisms in a Canine Model of Erythromycin‐Associated Long QT Syndrome , 1993, Circulation.

[35]  E. Mini,et al.  Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.

[36]  E. Mini,et al.  Clinical Pharmacokinetic Properties of the Macrolide Antibiotics , 2012 .

[37]  H. C. Hartzell,et al.  Modulation of the delayed rectifier potassium current in frog cardiomyocytes by beta‐adrenergic agonists and magnesium. , 1989, The Journal of physiology.

[38]  E. Mini,et al.  Clinical Pharmacokinetic Properties of the Macrolide Antibiotics , 1989, Clinical pharmacokinetics.

[39]  E. Mini,et al.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). , 1989, Clinical pharmacokinetics.